362 related articles for article (PubMed ID: 29109942)
1. Ductal Carcinoma
Gorringe KL; Fox SB
Front Oncol; 2017; 7():248. PubMed ID: 29109942
[TBL] [Abstract][Full Text] [Related]
2. Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression.
Wilson GM; Dinh P; Pathmanathan N; Graham JD
J Mammary Gland Biol Neoplasia; 2022 Mar; 27(1):101-131. PubMed ID: 35567670
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
[TBL] [Abstract][Full Text] [Related]
4. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cells and early stage basal-like breast cancer.
Lo PK; Wolfson B; Zhou Q
World J Obstet Gynecol; 2016 May; 5(2):150-161. PubMed ID: 28239564
[TBL] [Abstract][Full Text] [Related]
6. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
7. Ductal carcinoma in situ: a disease entity that merits more recognition.
Dereere E; Papadimitriou K; Tjalma W; Altintas S
Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193
[TBL] [Abstract][Full Text] [Related]
8. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
[TBL] [Abstract][Full Text] [Related]
9. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
10. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
[TBL] [Abstract][Full Text] [Related]
11. Progression from ductal carcinoma in situ to invasive breast cancer: revisited.
Cowell CF; Weigelt B; Sakr RA; Ng CK; Hicks J; King TA; Reis-Filho JS
Mol Oncol; 2013 Oct; 7(5):859-69. PubMed ID: 23890733
[TBL] [Abstract][Full Text] [Related]
12. Is loss of p53 a driver of ductal carcinoma in situ progression?
Morrissey RL; Thompson AM; Lozano G
Br J Cancer; 2022 Nov; 127(10):1744-1754. PubMed ID: 35764786
[TBL] [Abstract][Full Text] [Related]
13. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
14. Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies.
Hanna WM; Parra-Herran C; Lu FI; Slodkowska E; Rakovitch E; Nofech-Mozes S
Mod Pathol; 2019 Jul; 32(7):896-915. PubMed ID: 30760859
[TBL] [Abstract][Full Text] [Related]
15. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
16. Ductal carcinoma in situ on digital mammography versus digital breast tomosynthesis: rates and predictors of pathologic upgrade.
Kim G; Mikhael PG; Oseni TO; Bahl M
Eur Radiol; 2020 Nov; 30(11):6089-6098. PubMed ID: 32591884
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
18. Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis.
Rane SU; Mirza H; Grigoriadis A; Pinder SE
Breast Cancer Res Treat; 2015 Aug; 153(1):101-21. PubMed ID: 26255059
[TBL] [Abstract][Full Text] [Related]
19. Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.
Tokura M; Nakayama J; Prieto-Vila M; Shiino S; Yoshida M; Yamamoto T; Watanabe N; Takayama S; Suzuki Y; Okamoto K; Ochiya T; Kohno T; Yatabe Y; Suto A; Yamamoto Y
Cancer Res; 2022 Sep; 82(18):3236-3248. PubMed ID: 35852797
[TBL] [Abstract][Full Text] [Related]
20. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
